---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-027426"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:03:06.800262+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration

## Summary
- Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.
- OV329 Phase 1 single-ascending-dose portion completed with no safety signals; full data expected H1 2024.
- Entered license/collaboration with Graviton for ROCK2 inhibitors with $10M equity investment.
- Appointed Dr. Zhong Zhong CSO and Dr. Manoj Malhotra CMO; Meg Alexander promoted to Chief Strategy Officer.
- Implemented cost-cutting measures including G&A headcount reduction; cash runway expected into 2025.

## SEC filing metadata
- accession: 0001628280-23-027426
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/0001628280-23-027426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/ovid-20230804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-027426
- JSON: https://secwatch.observer/filing/0001628280-23-027426.json
- Plain text: https://secwatch.observer/filing/0001628280-23-027426.txt

## Key facts
- Earnings Releases
  Ovid Therapeutics Inc. reported financial results for second quarter ended June 30, 2023.
  - Period: second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 4, 2023, Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Second Quarter 2023 Financial Results and Corporate Updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636651/000162828023027426/0001628280-23-027426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.